Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer

Journal of Clinical Oncology

Volumn 31, Issue 14, 2013, Pages 1748-1757

  Castro, Elena ^a,b,s   Goh, Chee ^a,b   Olmos, David ^s   Saunders, Ed ^a   Leongamornlert, Daniel ^a   Tymrakiewicz, Malgorzata ^a   Mahmud, Nadiya ^a   Dadaev, Tokhir ^a   Govindasami, Koveela ^a   Guy, Michelle ^a   Sawyer, Emma ^a   Wilkinson, Rosemary ^a   Ardern Jones, Audrey ^b   Ellis, Steve ^f   Frost, Debra ^f   Peock, Susan ^f   Evans, D Gareth ^g   Tischkowitz, Marc ^f   Cole, Trevor ^h   Davidson, Rosemarie ⁱ   Eccles, Diana ^j   Brewer, Carole ^k   Douglas, Fiona ^l   Porteous, Mary E ^m   Donaldson, Alan ⁿ   Dorkins, Huw ^o   Izatt, Louise ^c   Cook, Jackie ^p   Hodgson, Shirley ^d   Kennedy, M John ^t   Side, Lucy E ^e   Eason, Jacqueline ^q   Murray, Alex ^r   Antoniou, Antonis C ^f   Easton, Douglas F ^f   Kote Jarai, Zsofia ^a   Eeles, Rosalind ^a,b   more..

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^d ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^e GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^f UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^g MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^h BIRMINGHAM CHILDREN S HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

ⁱ ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^j UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^k ROYAL DEVON AND EXETER HOSPITAL   (United Kingdom)

^l NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^m WESTERN GENERAL HOSPITAL   (United Kingdom)

ⁿ ST MICHAEL'S HOSPITAL   (United Kingdom)

^o Kennedy Galton Centre   (United Kingdom)

^p SHEFFIELD CHILDREN S HOSPITAL   (United Kingdom)

^q NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^r SINGLETON HOSPITAL   (United Kingdom)

^s Centro Nacional de Investigaciones Oncológicas   (Spain)

^t ST JAMES S HOSPITAL   (Ireland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; BRCA1 PROTEIN, HUMAN; BRCA2 PROTEIN, HUMAN;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CAUSE SPECIFIC SURVIVAL; DISTANT METASTASIS; FOLLOW UP; GENETIC ASSOCIATION; GERMLINE MUTATION; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS FREE SURVIVAL; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; RETROSPECTIVE STUDY; VERY ELDERLY; ADJUVANT THERAPY; BRACHYTHERAPY; CANCER GRADING; CANCER STAGING; GENETIC PREDISPOSITION; GENETICS; KAPLAN MEIER METHOD; LYMPH NODE; LYMPH NODE METASTASIS; METHODOLOGY; MIDDLE AGED; MORTALITY; MUTATION; NOMOGRAM; PALLIATIVE THERAPY; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSTATE TUMOR; PROSTATECTOMY; RISK ASSESSMENT; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRACHYTHERAPY; BRCA1 PROTEIN; BRCA2 PROTEIN; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HETEROZYGOTE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; NOMOGRAMS; PALLIATIVE CARE; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS;

MLCS; MLOWN;

EID: 84878450027     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.43.1882     Document Type: Article

References (40)

1. Ferlay J, Shin HR, Bray F, et al: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893-2917, 2010
2. Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin 61:69-90, 2011
3. Carter BS, Beaty TH, Steinberg GD, et al: Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci U S A 89:3367-3371, 1992
4. Eeles RA: Genetic predisposition to prostate cancer. Prostate Cancer Prostatic Dis 2:9-15, 1999
5. Edwards SM, Eeles RA: Unravelling the genetics of prostate cancer. Am J Med Genet C Semin Med Genet 129C:65-73, 2004
6. Lichtenstein P, Holm NV, Verkasalo PK, et al: Environmental and heritable factors in the causation of cancer: Analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 343:78-85, 2000
7. Eeles RA, Amin Al Olama A, Benlloch S, et al: Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nature Genetics 45:385-391, 2013
8. Cancer risks in BRCA2 mutation carriers: The Breast Cancer Linkage Consortium. J Natl Cancer Inst 91:1310-1316, 1999
9. Edwards SM, Kote-Jarai Z, Meitz J, et al: Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. Am J Hum Genet 72:1-12, 2003
10. Kote-Jarai Z, Leongamornlert D, Saunders E, et al: BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: Implications for genetic testing in prostate cancer patients. Br J Cancer 105:1230-1234, 2011
11. Leongamornlert D, Mahmud N, Tymrakiewicz M, et al: Germline BRCA1 mutations increase prostate cancer risk. Br J Cancer 106:1697-1701, 2012
12. Tryggvadóttir L, Vidarsdóttir L, Thorgeirsson T, et al: Prostate cancer progression and survival in BRCA2 mutation carriers. J Natl Cancer Inst 99:929-935, 2007
13. Mitra A, Fisher C, Foster CS, et al: Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype. Br J Cancer 98:502-507, 2008
14. Narod SA, Neuhausen S, Vichodez G, et al: Rapid progression of prostate cancer in men with a BRCA2 mutation. Br J Cancer 99:371-374, 2008
15. Gallagher DJ, Gaudet MM, Pal P, et al: Germline BRCA mutations denote a clinicopathologic subset of prostate cancer. Clin Cancer Res 16:2115-2121, 2010
16. Edwards SM, Evans DG, Hope Q, et al: Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis. Br J Cancer 103: 918-924, 2010
17. Thorne H, Willems AJ, Niedermayr E, et al: Decreased prostate cancer-specific survival of men with BRCA2 mutations from multiple breast cancer families. Cancer Prev Res (Phila) 4:1002-1010, 2011
18. Institute of Cancer Research: UK Genetic Prostate Cancer Study. www.icr.ac.uk/ukgpcs
19. University of Cambridge Centre for Cancer Genetic Epidemiology, School of Clinical Medicine: Epidemiological study of BRCA1 and BRCA2 mutation carriers. http://www.srl.cam.ac.uk/genepi/embrace/embrace_home.html
20. National Institute for Health and Clinical Excellence: Prostate cancer: Diagnosis and treatment CG58. 2008 http://publications.nice.org.uk/prostate-cancer-cg58
21. Mohler J, Bahnson RR, Boston B, et al: NCCN clinical practice guidelines in oncology: Prostate cancer. J Natl Compr Canc Netw 8:162-200, 2010
22. Kattan MW, Eastham JA, Stapleton AM, et al: A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 90:766-771, 1998
23. Graham J, Baker M, Macbeth F, et al: Diagnosis and treatment of prostate cancer: Summary of NICE guidance. BMJ 336:610-612, 2008
24. Gallagher DJ, Cronin AM, Milowsky MI, et al: Germline BRCA mutation does not prevent response to taxane-based therapy for the treatment of castration-resistant prostate cancer. BJU Int 109: 713-719, 2012
25. Fong PC, Boss DS, Yap TA, et al: Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361:123-134, 2009
26. Fong PC, Yap TA, Boss DS, et al: Poly(ADP)ribose polymerase inhibition: Frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 28:2512-2519, 2010
27. Tutt A, Robson M, Garber JE, et al: Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: A proof-of-concept trial. Lancet 376:235-244, 2010
28. Byrski T, Gronwald J, Huzarski T, et al: Patho-logic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 28:375-379, 2010
29. Yang D, Khan S, Sun Y, et al: Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA 306:1557-1565, 2011
30. Mitra AV, Bancroft EK, Barbachano Y, et al: Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: Preliminary analysis of the results of the IMPACT study. BJU Int 107:28-39, 2010
31. Schröder FH, Hugosson J, Roobol MJ, et al: Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360:1320-1328, 2009
32. Andriole GL, Crawford ED, Grubb RL 3rd, et al: Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360:1310-1319, 2009
33. Hugosson J, Carlsson S, Aus G, et al: Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 11:725-732, 2010
34. Chou R, Croswell JM, Dana T, et al: Screening for prostate cancer: A review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 155:762-771, 2011
35. Andriole GL, Crawford ED, Grubb RL 3rd, et al: Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: Mortality results after 13 years of follow-up. J Natl Cancer Inst 104:125-132, 2012
36. Williams N, Hughes LJ, Turner EL, et al: Prostate-specific antigen testing rates remain low in UK general practice: A cross-sectional study in six English cities. BJU Int 108:1402-1408, 2011
37. Giusti RM, Rutter JL, Duray PH, et al: A twofold increase in BRCA mutation related prostate cancer among Ashkenazi Israelis is not associated with distinctive histopathology. J Med Genet 40: 787-792, 2003
38. Grönberg H, Damber L, Tavelin B, et al: No difference in survival between sporadic, familial and hereditary prostate cancer. Br J Urol 82:564-567, 1998
39. Roehl KA, Loeb S, Antenor JA, et al: Characteristics of patients with familial versus sporadic prostate cancer. J Urol 176:2438-2442, 2006
40. Heck MM, Kron M, Gschwend JE, et al: Effect of family history on outcome in German patients treated with radical prostatectomy for clinically lo-calised prostate cancer. Eur J Cancer 48:1312-1317, 2012